Liver cancer medical device manufacturer and distributor, Sirtex Medical (SRX), was a standout performer for the quarter with its share price finishing up...

Liver cancer medical device manufacturer and distributor, Sirtex Medical (SRX), was a standout performer for the quarter with its share price finishing up 29.1%. In March 2015, the company will release trial data that has the potential to significantly increase the size of its addressable market. SRX hopes that its multi-year, 500 patient SIRFLOX trial, which compares the results of using SIR-Spheres with chemotherapy in patients with metastatic colorectal cancer versus chemotherapy on its own, will result in oncologists using the therapy as a front line treatment rather than merely a salvage treatment, as is currently the case. We have lightened our position into the share price strength, although the risk versus return profile still looks sufficiently compelling to justify our current portfolio weighting.